Frontier Medicines to Present Findings on PI3Kα-RAS Breaker FMC-242 and AI-Powered Frontier™ Platform at AACR Annual Meeting 2026

On March 17, 2026 Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, reported that it will present preclinical data on its FMC-242 program, as well as advances from its AI-powered Frontier Platform, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17-22, 2026, in San Diego. FMC-242 is Frontier’s first-in-class allosteric breaker of the PI3Kα-RAS interaction that is in preclinical development for the treatment of solid tumors driven by RTK activation, RAS mutations and PI3Kα mutations, as both a single agent and in combination with other therapies including KRAS inhibitors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to presenting new preclinical data at AACR (Free AACR Whitepaper) demonstrating that FMC-242 drives robust anti-tumor activity both as a monotherapy and in combination with targeted agents, while maintaining a favorable tolerability profile," said Kevin Webster, Ph.D., Chief Scientific Officer of Frontier Medicines. "These findings highlight the potential of selectively disrupting the PI3Kα-RAS interaction to address tumors driven by RTK activation and RAS mutations. Together with new data showcasing our AI-powered Frontier Platform, this work underscores how systematically mapping the proteome for covalent binding sites enables us to expand the range of high-value cancer targets we can drug and advance precision medicines for patients."

Summary of the findings to be presented and poster presentation details are as follows:

Title: FMC-242, a highly potent and selective covalent inhibitor of the PI3Kα-RAS interaction, demonstrates robust anti-tumor activity as monotherapy and in combination with targeted therapies
Poster Number: 5762
Session Title: Multi-Axis Antineoplastic Agents
Session Date & Time: April 21, 2026, 2:00 – 5:00 p.m. PT
Location: Poster Section 14, San Diego Convention Center
Summary of Findings: FMC-242 is a first-in-class, potent, selective, orally bioavailable covalent allosteric breaker of the PI3Kα-RAS interaction. In cell line- and patient-derived xenograft models with HER2 amplification and/or KRAS mutations, FMC-242 demonstrated potent anti-tumor activity with favorable tolerability and no effect on insulin signaling or blood glucose. In combination with EGFR inhibitors, KRASG12C inhibitors (including FMC-376), and pan-RAS/KRAS agents, FMC-242 further enhanced anti-tumor activity, supporting its potential as a differentiated monotherapy and combination approach.

Title: Finding Goldilocks: How AI-powered covalent drug discovery removes the "un" from "undruggable"
Poster Number: 4183
Session Title: Integrative Computational Approaches 2
Session Date & Time: April 21, 2026, 9:00 a.m. – 12:00 p.m. PT
Location: Poster Section 4, San Diego Convention Center
Summary of Findings: Application of the Frontier Platform, which integrates chemoproteomics, covalent chemistry, and machine learning, has enabled identification of selective covalent small-molecule leads across high-value cancer targets, including historically difficult drivers such as KEAP1, ADAR, DHX9, PTPN11, and MYC. The platform maps covalent binding sites across the proteome and applies AI-guided predictive modeling and optimized covalent fragment libraries to accelerate compound design, expanding the range of tractable oncogenic targets previously considered undruggable.

About FMC-242

FMC-242 is a first-in-class allosteric breaker of the PI3Kα-RAS interaction that breaks the interaction between PI3Kα and RAS to inhibit downstream signaling in tumors without impacting normal functions such as glucose homeostasis. The mechanism of action inhibits RAS driven PI3Kα-AKT signaling in tumors while minimizing the off-target effects and toxicities commonly associated with the broader class of kinase inhibitors. In preclinical models, FMC-242 has shown potent anti-tumor activity demonstrating the potential to impact patients with lung, colorectal, breast and other cancers that are driven by RTK activation, RAS mutation and PI3Kα mutations either as a single agent or in combination with other therapies including KRAS inhibitors. PI3Kα is the second most commonly mutated oncogene and plays an essential role in both KRAS- and RTK-driven cancers, such as colorectal, lung, and breast cancers, among others.

(Press release, Frontier Medicines, MAR 17, 2026, View Source [SID1234663650])

Pheast Therapeutics to Present Initial Phase 1a Clinical Data and Two New Preclinical Studies of PHST001, a Novel Anti-CD24 Antibody, at AACR 2026

On March 17, 2026 Pheast Therapeutics, a clinical-stage biotechnology company advancing macrophage-directed immunotherapies for cancer, reported that it will present three abstracts at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17–22 in San Diego.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations include initial data from the ongoing Phase 1 study of PHST001, an IgG4 anti-CD24 macrophage checkpoint inhibitor, in patients with advanced or metastatic solid tumors. Two additional preclinical abstracts evaluate PHST001 in combination with multiple classes of standard-of-care chemotherapy to enhance macrophage-mediated tumor cell clearance, and in metastatic tumor models assessing activity, Fc receptor contribution, and the impact of endogenous IgG competition.

"These presentations reflect the breadth of our work, from first-in-human evaluation to mechanistic and preclinical combination studies," said Roy Maute, Ph.D., Co-founder and Chief Executive Officer of Pheast Therapeutics. "Together, they provide important context as we advance PHST001 and develop a broad pipeline of macrophage-directed therapies for solid tumors."

"PHST001 was intentionally designed to balance effective CD24 blockade with controlled immune engagement," said Raphaël Rousseau, M.D., Ph.D., Chief Medical Officer of Pheast Therapeutics. "At AACR (Free AACR Whitepaper), we will present preliminary Phase 1a clinical data and supporting preclinical studies, as we evaluate PHST001 as a monotherapy and advance to combination settings."

AACR 2026 Presentation Details for PHST001

Initial Results from a Phase 1 Study of PHST001, a Macrophage Activating anti-CD24 Antibody, in Patients with Advanced/Metastatic Solid Tumors
Session Title: Phase 0 and First-in-Human Phase I Clinical Trials
Date & Time: Monday, April 20, 2PM–5PM PT
Location: Poster Section 51
Poster Board Number: 22
Abstract Presentation Number: CT130

PHST001 combination with standard-of-care chemotherapy enhances macrophage-mediated elimination of tumor cells
Session Title: Combination Immunotherapies
Date & Time: Monday, April 20, 9AM–12PM PT
Location: Poster Section 8
Poster Board Number: 11
Poster Number: 1557

PHST001, a humanized anti-CD24 hIgG4 antibody, is effective against metastatic tumors and retains its anti-tumor activity in the presence of competing IgG
Session Title: Monoclonal Antibodies and Antibody-Cytokine Platforms
Date & Time: Tuesday, April 21, 9AM–12PM PT
Location: Poster Section 9
Poster Board Number: 24
Poster Number: 4353

About CD24

CD24 is a cell surface protein that plays a key role in tumor immune evasion by engaging Siglec-10, an inhibitory receptor on macrophages. This interaction suppresses macrophage-mediated clearance of cancer cells, allowing tumors to escape destruction by the innate immune system. CD24 was identified as a novel macrophage checkpoint through foundational work by Dr. Amira Barkal, principal founder of Pheast. Along with other co-founders, Drs. Irving Weissman, Ravi Majeti, and Roy Maute, Pheast’s research opened the door to therapeutic strategies targeting CD24 to drive innate immune responses against cancer.

About PHST001

PHST001 is an anti-CD24 macrophage checkpoint inhibitor designed to overcome immune suppression in the tumor microenvironment. CD24 is highly expressed by many human cancers and high expression of CD24 is a negative prognostic factor in multiple cancer indications. Pheast has engineered PHST001 to be a potential best-in-class antibody designed to induce macrophages to phagocytose cancer cells and initiate a powerful immune response. PHST001-101 is an open-label, multicenter Phase 1 study in patients with advanced solid tumors (ClinicalTrials.gov Identifier: NCT06840886). Primary objectives include safety, tolerability, and dose optimization, with secondary objectives evaluating pharmacokinetics and preliminary anti-tumor activity.

(Press release, Pheast Therapeutics, MAR 17, 2026, View Source [SID1234663649])

Onchilles Pharma to Present New Preclinical Data on Systemically Delivered NEU-002 Program at AACR 2026

On March 17, 2026 Onchilles Pharma, a private biotech company advancing therapeutics targeting the ELANE pathway, reported that new preclinical data supporting its systemically delivered NEU-002 program will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17-22 in San Diego. The presentation will highlight the translational development of NEU-002, an engineered therapeutic elastase specifically designed for systemic administration, demonstrating anti-tumor activity via both intravenous and intraperitoneal delivery in solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"With our clinical-stage lead program, N17350, establishing the foundational proof-of-concept for the ELANE pathway, NEU-002 represents our second program and extends this approach into systemic delivery for solid tumors," said Court Turner, Co-Founder and Chief Executive Officer of Onchilles Pharma. "The data to be presented reflect our progress in engineering a systemically deliverable therapeutic that maintains anti-tumor activity and supports the advancement of NEU-002 toward development candidate selection and clinical translation."

Presentation Details

Title: Translational Development of NEU-002: Engineered Therapeutic Elastases Demonstrate Systemic Anti-Tumor Activity via Intraperitoneal and Intravenous Administration
Session Category: Experimental and Molecular Therapeutics
Session Title: Innovative Therapeutic Modalities and Translational Platforms
Day & Time: Saturday, April 19, from 2pm to 5pm PDT
Location: Poster Section 13
Poster Board Number: 28
Poster Number: 310

About Onchilles Therapeutic Programs Targeting the ELANE Pathway

At the core of this approach is the ELANE pathway, a unique cancer-selective killing mechanism that leverages a vulnerability shared by many cancer cell types: elevated histone H1 levels. Our pipeline is led by N17350, our first-in-class, clinical-stage program, followed by NEU-002, the second program that extends this approach with systemic delivery. By targeting the ELANE pathway and inducing immunogenic cancer cell death, N17350 and NEU-002 are designed to rapidly eliminate tumors while mobilizing an adaptive immune response, offering the potential for sustained anti-tumor immunity. N17350 and NEU-002 offer a unique approach to treating cancer regardless of their genetic makeup, anatomical origin, or immune status, positioning them as potential gamechangers in cancer therapy.

(Press release, Onchilles Pharma, MAR 17, 2026, View Source [SID1234663648])

SingleCell Biotechnology to Present High-Throughput Single-Cell Phenotyping Platform at AACR Annual Meeting

On March 17, 2026 SingleCell Biotechnology, a biotechnology company developing technologies to measure tumor cell behavior at single-cell resolution, reported that data from its platform will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, to be held in San Diego, April 17-21, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Relapse remains one of the most persistent challenges in oncology. While many therapies successfully reduce tumor size, a subset of tumor cells can survive treatment and later regenerate disease. These cells often exhibit behaviors, such as slow proliferation, migration or transient dormancy, that are difficult to detect using traditional preclinical models, where measurements are typically averaged across large populations of rapidly dividing tumor cells. As a result, promising drug candidates may advance through development without being evaluated against the cell populations most responsible for treatment resistance and recurrence.

SingleCell Biotechnology is developing a high-throughput single-cell phenotyping platform designed to measure tumor cell growth, migration and quiescent states at scale. The platform enables large-scale measurement of clonal tumor cell proliferation while preserving the diversity of cellular behaviors within tumors. By combining functional phenotyping with molecular analysis, the approach aims to provide deeper insight into tumor heterogeneity and support more informed decision-making in oncology drug discovery.

Presentation Details:

Poster Title: An Integrated High-throughput Assay for Proliferative Phenotypic and Omics
Presenter: Shiska Raut, Machine Learning Engineer
Location: Poster Section 51
Poster Board Number: 9
Session Date/Time: Sunday, April 19, 2026, 2:00 PM – 5:00 PM

(Press release, Single Cell Technology, MAR 17, 2026, View Source [SID1234663647])

Orum Therapeutics to Present New Preclinical Data on ORM-1153, a CD123-Targeting Degrader Antibody Conjugate, at the AACR Annual Meeting 2026

On March 17, 2026 Orum Therapeutics ("Orum" or the "Company") (KRX: 475830), a biotechnology company pioneering the field of degrader antibody conjugates (DACs), reported that new preclinical data on ORM-1153, a CD123-targeting DAC designed to selectively deliver a proprietary GSPT1-degrading payload for the treatment of acute myeloid leukemia (AML), will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, taking place April 17-22 in San Diego.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Orum’s two posters on ORM-1153 will highlight preclinical efficacy, pharmacology, and non-human primate safety findings that support advancement toward clinical development in AML.

"The data being presented at AACR (Free AACR Whitepaper) reflect continued progress for ORM-1153 and Orum’s Dual-Precision TPD² approach," said Sung Joo (SJ) Lee, Ph.D., Founder and CEO of Orum. "These preclinical data, including repeat-dose non-human primate studies, support advancement toward clinical development and underscore the potential of our approach to expand the therapeutic window beyond conventional cytotoxic antibody-drug conjugates."

Orum’s AACR (Free AACR Whitepaper) 2026 Presentation Details
Both posters will be presented on Monday, April 20, from 9 am to 12 pm PDT.

ORM-1153: A Novel CD123-Targeting Degrader Antibody Conjugate with Proprietary GSPT1 Degrading Payload for the Treatment of Acute Myeloid Leukemia
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody-Drug Conjugates and Linker Engineering 2
Location: Poster Section 13
Poster Board Number: 7
Poster Number: 1710

ORM-1153: A Next-Generation CD123-Targeting Degrader Antibody Conjugate (DAC)
Session Category: Experimental and Molecular Therapeutics
Session Title: Quantitative Pharmacology and Translational Modeling
Location: Poster Section 17
Poster Board Number: 12
Poster Number: 1824
Posters will be available on Orum’s website following the presentation.

About ORM-1153

ORM-1153 is a CD123-targeting degrader antibody conjugate developed using Orum’s Dual-Precision TPD² approach. The molecule conjugates a proprietary GSPT1-degrading payload to an anti-CD123 antibody with high internalization efficiency via a β-glucuronide cleavable linker. By combining tumor-selective antibody delivery with targeted protein degradation, ORM-1153 is designed to induce cancer cell death through degradation of GSPT1, a protein implicated in cell survival, including in TP53-mutant AML, while minimizing effects on normal tissues.

About Orum’s TPD² Approach

Orum’s unique Dual-Precision Targeted Protein Degradation (TPD²) approach builds novel targeted protein degraders combined with the precise cell delivery mechanisms of antibodies to generate innovative, first-in-class, cell-selective TPDs for the treatment of cancer and other serious diseases. Orum has developed new targeted protein degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, the payloads are designed to be delivered specifically to target cells and precisely degrade the intracellular target protein of interest.

(Press release, Orum Therapeutics, MAR 17, 2026, View Source [SID1234663646])